Phase II Study of QLC2519 in Pediatric Solid Tumor Participants
A phase 2 trial of Albipagrastim alf in childhood cancers, run by Qilu Pharmaceutical Co., Ltd., now recruiting.
Overview
Phase II Study of QLC2519 in Pediatric Solid Tumor Participants is a phase 2 interventional study registered as NCT07724756 by Qilu Pharmaceutical Co., Ltd., with 18 participants planned, started 2026-06-26 and due to reach its primary completion in 2027-06-26. Interventions recorded: Albipagrastim alf.
Similar pages
not linked directly; found by shared links- TrialOpen-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC
Shares Childhood cancers (all types) and the tag pipeline.
- TrialGM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer
Shares Qilu Pharmaceutical and the tag pipeline.
- TrialPK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Shares Childhood cancers (all types) and the tag pipeline.
- TrialPhase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients
Shares Qilu Pharmaceutical and the tag pipeline.
- TrialStudy to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
Shares Childhood cancers (all types) and the tag pipeline.
- TrialStudy of MHB088C for Patients With Advanced Solid Malignant Tumors
Shares Qilu Pharmaceutical and the tag pipeline.
- TrialCEB-01 in Paediatrics With Locally Resectable Abdominal Tumours
Shares Childhood cancers (all types) and the tag pipeline.
- TrialInvestigation of Remimazolam in Children Undergoing Sedation for Medical Procedures
Shares Childhood cancers (all types) and the tag pipeline.